David J. Dow
Impact in
- Pharmacology top 5%
- Drug-Induced Adverse Reactions
- Pharmacogenetics and Drug Metabolism
- Virology top 5%
- HIV Research and Treatment
Papers in
-
- CRISPR and Genetic Engineering 4
- RNA and protein synthesis mechanisms 2
- Ubiquitin and proteasome pathways 2
- Genetics 6
- Virus-based gene therapy research 2
- Genetics and Neurodevelopmental Disorders 2
- Co-authors
- Allen D. Roses (2 shared papers)William Spreen (1 shared paper)Michael Stocum (1 shared paper)Linda M. Thurmond (1 shared paper)Seth Hetherington (1 shared paper)Denise Shortino (1 shared paper)Arlene R. Hughes (1 shared paper)Katherine L. Baker-Neblett (1 shared paper)
- Journals
- Journal of Medical Genetics (2 papers)Molecular Therapy (1 paper)Human Molecular Genetics (1 paper)Drug Discovery Today (1 paper)The Lancet (1 paper)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
David J. Dow
15 papers receiving 1.1k citations
David J. Dow's Hit Papers
Peers
Comparison fields: 5 of 88
- Pharmacology 327
- Virology 80
- Pharmacology 111
- Cellular and Molecular Neuroscience 173
- Toxicology 29
Countries citing papers authored by David J. Dow
This map shows the geographic impact of David J. Dow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Dow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Dow more than expected).
Fields of papers citing papers by David J. Dow
This network shows the impact of papers produced by David J. Dow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Dow. The network helps show where David J. Dow may publish in the future.
Co-authors
The 25 scholars most cited alongside David J. Dow, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Genetic variations in HLA-B region and hypersensitivity reactions to abacavir Hit paper breakdown → | 2002 | 583 |
| 2 | 1996 | 208 | |
| 3 | 2019 | 78 | |
| 4 | 2011 | 38 | |
| 5 | A study of FRAXE in mentally retarded individuals referred for fragile X syndrome (FRAXA) testing in the United Kingdom. | 1996 | 37 |
| 6 | 1993 | 31 | |
| 7 | 2011 | 31 | |
| 8 | 2019 | 21 | |
| 9 | 2017 | 12 | |
| 10 | 2005 | 11 | |
| 11 | 1999 | 11 | |
| 12 | 1998 | 8 | |
| 13 | 2010 | 6 | |
| 14 | 2006 | 6 | |
| 15 | 1997 | 4 |
About David J. Dow
David J. Dow is a scholar working on Molecular Biology, Genetics, Oncology, Pharmacology and Cellular and Molecular Neuroscience, having authored 15 papers that have together received 1.1k indexed citations. Recurring topics across this work include CRISPR and Genetic Engineering (4 papers), Virus-based gene therapy research (2 papers), CAR-T cell therapy research (2 papers), Genetic Neurodegenerative Diseases (2 papers), Cancer Genomics and Diagnostics (2 papers), RNA and protein synthesis mechanisms (2 papers), Genetics and Neurodevelopmental Disorders (2 papers) and Ubiquitin and proteasome pathways (2 papers). The work is most often cited by research in Pharmacology (327 citations), Virology (80 citations), Pharmacology (111 citations), Cellular and Molecular Neuroscience (173 citations) and Toxicology (29 citations). David J. Dow has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Allen D. Roses, William Spreen, Michael Stocum, Linda M. Thurmond, Seth Hetherington, Denise Shortino, Arlene R. Hughes, Katherine L. Baker-Neblett, Eric Lai and Mary E. Fling. Their work appears in journals such as Journal of Medical Genetics, Molecular Therapy, Human Molecular Genetics, Drug Discovery Today and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.